| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenues and other income | 115,461 | 47,627 | ||
| Cost of captisol | 3,801 | 2,907 | ||
| Amortization of intangibles | 8,097 | 8,258 | ||
| Research and development | 21,019 | 6,567 | ||
| General and administrative | 28,446 | 20,175 | ||
| Financial royalty assets impairment | 0 | 0 | ||
| Fair value adjustments to partner program derivatives | 833 | -1,276 | ||
| Total operating costs and expenses | 60,530 | 39,183 | ||
| Operating income (loss) | 54,931 | 8,444 | ||
| Gain (loss) from short-term investments | 7,798 | 939 | ||
| Gain (loss) from change in fair value of equity-method investments and other investments | 75,887 | - | ||
| Interest income | 3,874 | 1,621 | ||
| Interest expense | 910 | 1,153 | ||
| Other non-operating expense, net | -443 | 1,372 | ||
| Total non-operating income (expenses), net | 86,206 | 2,779 | ||
| Income (loss) before income taxes | 141,137 | 11,223 | ||
| Income tax expense | 23,864 | 6,376 | ||
| Net income (loss) | 117,273 | 4,847 | ||
| Basic net income (loss) per share (in usd per share) | 5.99 | 0.25 | ||
| Diluted net income (loss) per share (in usd per share) | 5.68 | 0.24 | ||
| Shares used in basic per share calculation (in shares) | 19,578,000 | 19,327,000 | ||
| Shares used in diluted per share calculation (in shares) | 20,629,000 | 19,926,000 | ||
LIGAND PHARMACEUTICALS INC (LGNDZ)
LIGAND PHARMACEUTICALS INC (LGNDZ)